MedPath

Evaluating the effect of atorvastatin on kidney stone.

Not Applicable
Conditions
Calcium kidney stone.
Calculus of kidney
Registration Number
IRCT2017021826406N2
Lead Sponsor
rology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
30
Inclusion Criteria

History of calcium kidney stone (stone should be radio-opaque in radiological evaluation); at least 2 times of kidney stone episodes (Recurrent stone); at least 20 days since the last treatment; age 18 to 65 years; Hyperoxaluria (24-hour urine oxalate over 40 and less than 80 mg); willingness to cooperate in the study.

Exclusion criteria: Primary or enteric hyperoxaluria (urine oxalate>80 mg/24h);taking any drugs or supplements with antioxidant or anti-inflammatory effects (e.g. steroids, Nonsteroidal Antiinflammatory Drugs, pioglitazone, …), multivitamins containing vitamin A,C or E and any supplement containing anti-oxidants; History of diabetes mellitus, hepatic failure, thyroid or parathyroid diseases, cancers or immunologic diseases, chronic kidney disease (Glomerular filtration rate< 60), Urinary tract infection and chronic diarrhea; Pregnancy or lactation

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
rine malondialdehyde. Timepoint: Before the intervention, 3 months after the intervention. Method of measurement: colorimetric method using Thiobarbituric acid.;Urine neutrophil gelatinase-associated lipocalin. Timepoint: Before the intervention, 3 months after the intervention. Method of measurement: ELISA.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath